{"product_id":"generic-belzutifan-welidx","title":"WELIDX (Belzutifan)","description":"\u003ch2\u003eAbout  Belzutifan\u003c\/h2\u003e\u003cp\u003eBelzutifan is an hypoxia-inducible factor-2 alpha inhibitor. \u003c\/p\u003e\u003cp\u003eBelzutifan is used to treat von Hippel-Lindau (VHL) disease in patients who need treatment for kidney cancer (renal cell carcinoma), brain and spinal cord tumors (CNS hemangioblastomas), or pancreatic cancer (pancreatic neuroendocrine tumor [pNET]) that do not require surgery right away.\u003c\/p\u003e\u003ch2\u003eVon Hippel-Lindau Disease\u003c\/h2\u003e\u003cp\u003eIndicated for adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery\u003c\/p\u003e\u003cp\u003e120 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eRenal Cell Carcinoma\u003c\/h2\u003e\u003cp\u003eIndicated for advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)\u003c\/p\u003e\u003cp\u003e120 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003ch3\u003eDose reductions for adverse reactions\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 80 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird dose reduction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eAnemia\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eHemoglobin \u0026lt;9 g\/dL or transfusion indicated: Withhold until hemoglobin ≥8 g\/dL; resume at same or reduced dose; or discontinue depending on severity of anemia\u003c\/li\u003e\n\u003cli\u003eLife-threatening or urgent intervention indicated: Withhold until hemoglobin ≥8 g\/dL; resume at a reduced dose or permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHypoxia\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eDecreased oxygen saturation with exercise (eg, pulse oximeter \u0026lt;88%): Consider withholding until resolved; resume at same dose or at reduced dose depending on severity\u003c\/li\u003e\n\u003cli\u003eDecreased oxygen saturation at rest (eg, pulse oximeter \u0026lt;88% or PaO\u003csub\u003e2\u003c\/sub\u003e ≤55 mm Hg) or urgent intervention indicated: Withhold until resolved; resume at reduced dose or discontinue depending on severity\u003c\/li\u003e\n\u003cli\u003eLife-threatening or recurrent symptomatic hypoxia: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eOther adverse reactions\u003c\/h3\u003e\u003cp\u003eGrade 3: Withhold until resolved to Grade ≤2; consider resuming at a reduced dose (reduce by 40 mg)\u003c\/p\u003e\u003cp\u003eRecurrent Grade 3 or Grade 4: Permanently discontinue\u003c\/p\u003e\u003ch3\u003eRenal impairment\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (eGFR 30-89 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR 15-29 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatic impairment\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin [TB] ≤ULN and AST \u0026gt;ULN or TB \u0026gt;1 to 1.5x ULN and any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe hepatic impairment (TB \u0026gt;1.5x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of childbearing potential before initiation\u003c\/p\u003e\u003cp\u003eClosely monitor for adverse reactions in patients who are dual UGT2B17 and CYP2C19 poor metabolizers\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953343531,"sku":"RL3020241030","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2281.jpg?v=1787022200","url":"https:\/\/xomeds.com\/products\/generic-belzutifan-welidx","provider":"XOMEDS","version":"1.0","type":"link"}